Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Insurance
February 01, 2015 11:00 PM

Insurers eye pharma discounts beyond hepatitis C

Bob Herman
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    The pricing battle pitting insurers and pharmacy benefit managers against drugmakers over a new breed of high-priced and highly effective treatments for hepatitis C may be a preview of tougher negotiations for coverage of other blockbuster drugs.

    Harvard Pilgrim Health Care's chief medical officer, Dr. Michael Sherman, told Modern Healthcare a new class of cholesterol drugs will be “the next shock to the system,” prompting payers and drug companies to initiate similar rebate conversations.

    Last week, Harvard Pilgrim, headquartered in Wellesley, Mass., struck a one-year deal with Gilead Sciences. That agreement put Gilead's newest hepatitis C drug, Harvoni, which costs $94,500 for a regular course of treatment, on Harvard Pilgrim's preferred coverage list for members. In exchange, Harvard Pilgrim got a discount.

    Harvard Pilgrim spent $25 million on hepatitis C drugs for about 300 members last year, which spurred the insurer to negotiate down those higher-than-expected costs. “We, like most other health plans, had not budgeted for that,” Sherman said. “They were priced as if they were serving an orphan-drug population.”

    Several other large companies have reached similar deals with Gilead for Harvoni or its other breakthrough hepatitis C drug, Sovaldi. Those include Aetna, Anthem, Humana, UnitedHealthcare, CVS Health and EnvisionRx.

    The agreements proliferated quickly after Express Scripts said in late December that AbbVie's new Viekira Pak would be the primary option for its members.

    Express Scripts is one of the few large players that publicly chose AbbVie over Gilead, although several Blue Cross and Blue Shield plans, such as Blue Shield of California, have picked Viekira as their preferred hepatitis C drug. Some state Medicaid programs have done the same. Missouri, for example, said last week it chose Viekira for its hepatitis C patients who meet certain medical criteria. Missouri expects the deal will save $4.2 million in 2016. Prime Therapeutics, a pharmacy benefit manager owned by 13 Blue Cross plans, said both companies' hepatitis C drugs were on its preferred drug list.

    The emergence of AbbVie's drug resulted in price competition and chipped away at Gilead's hold on the market. Observers say the same could happen with a new cohort of potential breakthrough drugs, which is making its way through the federal approval process.

    Sanofi and Regeneron Pharmaceuticals are partnering on a class of drugs that treats people with high cholesterol. Amgen is working on a similar project, specifically involving PCSK9 inhibitors.

    The drugs are intended to help treat high cholesterol for people who do not respond to statins. Prices for the new cholesterol drugs are expected to be between $4,000 and $8,000 for a course of treatment but could be more, Sherman said.

    The drugs will certainly cost less than the hepatitis C drug regimens. But because high cholesterol affects a much larger swath of the American public—the Centers for Disease Control and Prevention estimates 71 million people have high cholesterol levels—analysts say the manufacturers stand to make billions of dollars in new revenue.

    “The drug companies and analysts are thinking blockbuster, and we're thinking, 'How do we pay for this?'” Sherman said. “I can assure you we will be negotiating with both (groups of drug) companies.”

    AbbVie CEO Richard Gonzalez told investors last week the company estimates Viekira will bring in $3 billion in sales by the end of this year. Gilead has already reaped massive revenue and profit from its hepatitis C drugs.

    Follow Bob Herman on Twitter: @MHbherman

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Elevance Health
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    Sachin Jain ai
    SCAN Group approaching AI cautiously, CEO says
    Most Popular
    1
    CMS tries luring providers to revamped Medicare ACOs
    2
    Oregon joins other states in setting ratios for nurse staffing
    3
    Blue Shield CA taps Amazon, Mark Cuban, CVS for new PBM model
    4
    A health innovation hub grows in Lake Nona Medical City
    5
    Hospital-at-home providers push for Medicaid coverage
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing